Proteostasis Therapeutics Inc.
Funding rounds
4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2022 | $8 M | Issued in a merger or acquisition | $2 to $10 million | equity | SEC | |
| Dec 2020 | $34 M | No. 4 | $10 to $50 million | equity | SEC | |
| Sep 2015 | $22 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| Jul 2014 | $15 M | No. 2 | $10 to $50 million | debt, options | SEC | |
| Aug 2008 | $71 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Proteostasis Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).
SEC Form D · Dec 2022
The industry group it chose in its notices: Other Health Care.
SEC Form D · Dec 2022
That is all the official record says: Proteostasis Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: its website did not answer.
Investors#
15 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Elan Pharma International LTD. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Franklin M. Berger | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2016) | SEC Form 3 |
| HealthCare Partners VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| HealthCare Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| HealthCare Ventures VIII, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Nea 12 GP, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| NEA Partners 12, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| New Enterprise Associates 12, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Novartis AG | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Novartis Bioventures Ltd | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| PERRIGO Co PLC | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Perrigo Corp LTD. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Perrigo Holdings LTD. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Perrigo Science One LTD. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 16 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Craig W. Philips | Executive officer | Dec 2022 |
| Keith A. Baker | Executive officer | Dec 2022 |
| Shawn Iadonato | Executive officer | Dec 2022 |
| Brigitte Robertson | Executive officer | Jan 2021 |
| N. Anthony Coles | Executive officer | Jan 2021 |
| Paulash Mohsen | Executive officer | Jan 2021 |
| Richard Peters | Executive officer | Jan 2021 |
| Janet James Smart | Executive officer | Sep 2015 |
| Janet T. Smart | Executive officer | Sep 2015 |
| Meenu James Chhabra | Executive officer | Sep 2015 |
| Nadia James Ustariz | Executive officer | Sep 2015 |
| Nadia T. Ustariz | Executive officer | Sep 2015 |
| Janet Smart | Executive officer | Oct 2014 |
| Markus Haeberlein | Executive officer | Oct 2014 |
| Meenu Chhabra | Executive officer | Oct 2014 |
| Michael Casey | Executive officer | Oct 2014 |
| Walter Newman | Executive officer | Oct 2014 |
| Jeffrey Goldberg | Executive officer | Aug 2014 |
| Pauline Jen Ryan | Treasurer and Secretary of the Issuer | Jun 2011 |
| Peter H. Reinhart | President and Chief Scientific Officer of the Issuer | Jun 2011 |
| David Arkowitz | Director | Dec 2022 |
| Marion R. Foote | Director | Dec 2022 |
| Raymond Bartoszek | Director | Dec 2022 |
| Richard Peters | Director | Dec 2022 |
| Shawn Iadonato | Director | Dec 2022 |
| Cecil B. Pickett | Director | Jan 2021 |
| David L. Arkowitz | Director | Jan 2021 |
| Jeffery W. Kelly | Director | Jan 2021 |
| Kim C. Drapkin | Director | Jan 2021 |
| Lynne B. Zydowsky | Director | Jan 2021 |
| N. Anthony Coles | Director | Jan 2021 |
| Patricia L. Allen | Director | Jan 2021 |
| Richard A. Heyman | Director | Jan 2021 |
| Bernard James Davitian | Director | Sep 2015 |
| Christopher James Mirabelli | Director | Sep 2015 |
| Christopher James Walsh | Director | Sep 2015 |
| Christopher K. Mirabelli | Director | Sep 2015 |
| Christopher T. Walsh | Director | Sep 2015 |
| Conor James Walshe | Director | Sep 2015 |
| Conor T. Walshe | Director | Sep 2015 |
About
Company in Boston, United States.